Safety
death, shock, TEAEs, anemia, TRAEs
SHOCK, ADVERSE EVENTS, DISEASE, ANEMIA, ADVERSE EVENT
The mean ± SD duration of exposure to senaparib was 126.5 ± 122.2 days (range, 22-576 days) across the dose-escalation and dose-expansion periods (All 57 patients enrolled in the study experienced at least one TEAE (Fifty-five (96.5%) patients experienced senaparib-related adverse events (TRAEs) (Incidence of senaparib-related treatment-emergent adverse events occurring in ≥10% of patients, any grade and grade ≥3, by preferred term (dose escalation and dose expansion phases; safety analysis set, 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; Gr≥3, grade ≥3; QD, once daily; TRAE, treatment (senaparib)-related adverse event; WBC, white blood cell.TEAEs causing dose interruption, dose reduction, and study drug discontinuation occurred in 15 (26.3%), 8 (14.0%), and 6 (10.5%) patients, respectively. The only TEAE causing study drug discontinuation in more than one patient across the dose groups was anemia (TEAEs resulted in death for 2 (3.5%) patients, 1 in the 20-mg dose group (advanced disease/hemorrhagic shock), and 1 in the 80-mg dose group (disease progression/ileus—unconfirmed). Neither was considered to be related to senaparib.